185 related articles for article (PubMed ID: 30552913)
1. Epinecidin-1: A marine fish antimicrobial peptide with therapeutic potential against Trichomonas vaginalis infection in mice.
Huang HN; Chuang CM; Chen JY; Chieh-Yu P
Peptides; 2019 Feb; 112():139-148. PubMed ID: 30552913
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of three synthetic peptides derived from epinecidin-1 and an anti-lipopolysaccharide factor against Propionibacterium acnes, Candida albicans, and Trichomonas vaginalis.
Pan CY; Chen JY; Lin TL; Lin CH
Peptides; 2009 Jun; 30(6):1058-68. PubMed ID: 19463737
[TBL] [Abstract][Full Text] [Related]
3. In vitro effect of octenidine dihydrochloride against Trichomonas vaginalis.
Küng E; Pietrzak J; Klaus C; Walochnik J
Int J Antimicrob Agents; 2016 Mar; 47(3):232-4. PubMed ID: 26899578
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of circulating antibody response to Trichomonas vaginalis: clinical and diagnostic implications.
Ton Nu PA; Rappelli P; Dessì D; Nguyen VQ; Fiori PL
Sex Transm Infect; 2015 Dec; 91(8):561-3. PubMed ID: 25887282
[TBL] [Abstract][Full Text] [Related]
5. 20S Proteasome as a Drug Target in Trichomonas vaginalis.
O'Donoghue AJ; Bibo-Verdugo B; Miyamoto Y; Wang SC; Yang JZ; Zuill DE; Matsuka S; Jiang Z; Almaliti J; Caffrey CR; Gerwick WH; Eckmann L
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451503
[TBL] [Abstract][Full Text] [Related]
6. Antiparasitic activity of furanyl N-acylhydrazone derivatives against Trichomonas vaginalis: in vitro and in silico analyses.
Alves MSD; das Neves RN; Sena-Lopes Â; Domingues M; Casaril AM; Segatto NV; Nogueira TCM; de Souza MVN; Savegnago L; Seixas FK; Collares T; Borsuk S
Parasit Vectors; 2020 Feb; 13(1):59. PubMed ID: 32046788
[TBL] [Abstract][Full Text] [Related]
7. Metronidazole resistance in Trichomonas vaginalis from highland women in Papua New Guinea.
Upcroft JA; Dunn LA; Wal T; Tabrizi S; Delgadillo-Correa MG; Johnson PJ; Garland S; Siba P; Upcroft P
Sex Health; 2009 Dec; 6(4):334-8. PubMed ID: 19917203
[TBL] [Abstract][Full Text] [Related]
8. The antimicrobial peptides LL-37, KR-20, FK-13 and KR-12 inhibit the growth of a sensitive and a metronidazole-resistant strain of Trichomonas vaginalis.
Ramírez-Ledesma MG; Rodríguez MC; Alva-Murillo N; Avila EE
Parasitol Res; 2022 Dec; 121(12):3503-3512. PubMed ID: 36171407
[TBL] [Abstract][Full Text] [Related]
9. Anti-Trichomonas vaginalis activity of ursolic acid derivative: a promising alternative.
Bitencourt FG; de Brum Vieira P; Meirelles LC; Rigo GV; da Silva EF; Gnoatto SCB; Tasca T
Parasitol Res; 2018 May; 117(5):1573-1580. PubMed ID: 29572567
[TBL] [Abstract][Full Text] [Related]
10. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo.
Hopper M; Yun JF; Zhou B; Le C; Kehoe K; Le R; Hill R; Jongeward G; Debnath A; Zhang L; Miyamoto Y; Eckmann L; Land KM; Wrischnik LA
Int J Antimicrob Agents; 2016 Dec; 48(6):690-694. PubMed ID: 27839893
[TBL] [Abstract][Full Text] [Related]
11. Use of intravaginal microbicides to prevent acquisition of Trichomonas vaginalis infection in Lactobacillus-pretreated, estrogenized young mice.
Lushbaugh WB; Blossom AC; Shah PH; Banga AK; Jaynes JM; Cleary JD; Finley RW
Am J Trop Med Hyg; 2000; 63(5-6):284-9. PubMed ID: 11421379
[TBL] [Abstract][Full Text] [Related]
12. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.
Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE
Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623
[TBL] [Abstract][Full Text] [Related]
13. Drug repositioning for novel antitrichomonas from known antiprotozoan drugs using hierarchical screening.
Meneses-Marcel A; Marrero-Ponce Y; Ibáñez-Escribano A; Gómez-Barrio A; Escario JA; Barigye SJ; Terán E; García-Jacas CR; Machado-Tugores Y; Nogal-Ruiz JJ; Arán-Redó VJ
Future Med Chem; 2018 Apr; 10(8):863-878. PubMed ID: 29589477
[TBL] [Abstract][Full Text] [Related]
14. The genetic diversity of metronidazole susceptibility in Trichomonas vaginalis clinical isolates in an Egyptian population.
Abdel-Magied AA; El-Kholya EI; Abou El-Khair SM; Abdelmegeed ES; Hamoudaa MM; Mohamed SA; El-Tantawy NL
Parasitol Res; 2017 Nov; 116(11):3125-3130. PubMed ID: 28956167
[TBL] [Abstract][Full Text] [Related]
15. Challenges and Persistent Questions in the Treatment of Trichomoniasis.
de Brum Vieira P; Tasca T; Secor WE
Curr Top Med Chem; 2017; 17(11):1249-1265. PubMed ID: 27697044
[TBL] [Abstract][Full Text] [Related]
16. Premature with trichomoniasis: report of one case.
Wang JJ; Yeung LK; Sun LC; Sy LB; Leu FJ
Acta Paediatr Taiwan; 2005; 46(4):219-21. PubMed ID: 16381336
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the in vitro activity of ceragenins against Trichomonas vaginalis.
Polat ZA; Cetin A; Savage PB
Acta Parasitol; 2016 Mar; 61(2):376-81. PubMed ID: 27078662
[TBL] [Abstract][Full Text] [Related]
18. Effects of SQ109 on Trichomonas vaginalis.
de Souza TG; Granado R; Benaim G; de Souza W; Benchimol M
Exp Parasitol; 2023 Jul; 250():108549. PubMed ID: 37196704
[TBL] [Abstract][Full Text] [Related]
19. Effect of the antimicrobial peptide tritrpticin on the in vitro viability and growth of Trichomonas vaginalis.
Infante VV; Miranda-Olvera AD; De Leon-Rodriguez LM; Anaya-Velazquez F; Rodriguez MC; Avila EE
Curr Microbiol; 2011 Jan; 62(1):301-6. PubMed ID: 20640424
[TBL] [Abstract][Full Text] [Related]
20. Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.
Bouchemal K; Bories C; Loiseau PM
Clin Microbiol Rev; 2017 Jul; 30(3):811-825. PubMed ID: 28539504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
